Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Precision BioSciences, Inc. reports developments for a clinical-stage gene editing company using its proprietary ARCUS platform to develop in vivo therapies for diseases with high unmet need. Company news centers on PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, including clinical-program updates, regulatory clearances and designations, scientific-meeting presentations, and data from the ELIMINATE-B and FUNCTION-DMD studies.
Recurring updates also include quarterly financial results, cash runway commentary, business priorities, and equity-compensation grants under Nasdaq inducement-award rules. Precision describes ARCUS applications across gene elimination, excision, and insertion, with program-specific disclosures tied to viral DNA, cccDNA, defective-gene removal, and AAV delivery.
Precision BioSciences (NASDAQ: DTIL) reported a pivotal 2020, achieving significant advancements in its ARCUS genome editing and CAR T programs. The company announced a collaboration with Eli Lilly for developing gene therapies, receiving $100 million upfront. Financially, total revenues rose to $24.3 million, while R&D expenses increased to $98.1 million, reflecting growth in clinical programs. However, the net loss widened to $109 million, or $(2.09) per share. Key milestones for 2021 include initiating the PBCAR19B clinical trial and reporting interim data for multiple CAR T programs.
Precision BioSciences, Inc. (Nasdaq: DTIL) will release its fourth quarter and fiscal year 2020 financial results and a business update on March 18, 2021. The company focuses on improving lives through its ARCUS® genome editing platform, which enables the development of CAR T immunotherapy clinical candidates and gene correction therapies. These advancements aim to address genetic and infectious diseases lacking adequate treatment options. For more information, visit www.precisionbiosciences.com.
Precision BioSciences (Nasdaq: DTIL) announced participation in two upcoming virtual investor conferences on March 9, 2021. The first is the H.C. Wainwright Global Life Sciences Conference, featuring an on-demand fireside chat starting at 7:00 AM ET. The second is the Barclays Global Healthcare Conference, with a presentation scheduled for 10:55 AM ET. Both events will be accessible via the company's website, ensuring investors can stay informed.
Precision BioSciences (Nasdaq: DTIL) announced a significant publication in Molecular Therapy detailing three-year follow-up results from a study on PCSK9 gene editing via its ARCUS® platform.
The study demonstrated a long-term reduction of LDL cholesterol levels by up to 56% in nonhuman primates after a single treatment, with stable reductions in PCSK9 protein levels by 85%. This data supports the potential for a one-time therapeutic approach to familial hypercholesteremia and highlights the efficacy and safety of ARCUS technology.
Precision BioSciences (Nasdaq: DTIL), a clinical stage biotechnology company, announced its participation in the Guggenheim Healthcare Talks 2021 Oncology Day on February 11, 2021, at 2:00 PM ET. A live webcast of the presentation will be available on the company’s website in the Investors & Media section. Precision BioSciences is focused on improving life through its proprietary ARCUS genome editing platform, which aims to develop CAR T immunotherapy and gene correction therapies for genetic and infectious diseases.
Precision BioSciences (Nasdaq: DTIL) announced a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering its PBCAR19B product candidate aimed at treating relapsed/refractory Non-Hodgkin Lymphoma (NHL). The patent will encompass genetically-modified human T cells utilizing Precision's ARCUS genome editing platform, with an expected expiration date in April 2040. PBCAR19B is designed to enhance CAR T cell persistence by reducing rejection from T cells and natural killer cells. The Phase 1 clinical study is anticipated to commence by mid-2021.
Precision BioSciences announced that the FDA has accepted its Investigational New Drug (IND) application for PBCAR19B, a candidate for treating relapsed/refractory Non-Hodgkin Lymphoma (NHL).
This Phase 1 trial is set to evaluate the safety and effectiveness of PBCAR19B. The trial aims to identify the maximum tolerated dose and any adverse effects at varying dose levels.
CEO Matt Kane expressed optimism regarding PBCAR19B's potential to improve allogeneic CAR T cell persistence, alongside ongoing efforts with PBCAR0191.
DURHAM, N.C., Jan. 07, 2021 – Precision BioSciences, Inc. (Nasdaq: DTIL) announced the closure of its in vivo gene editing collaboration and exclusive license agreement with Eli Lilly, following regulatory clearance. The collaboration focuses on using Precision's ARCUS genome editing platform for up to six gene targets, including Duchenne muscular dystrophy. Precision receives $100 million upfront and has already received $35 million from share purchases. They are eligible for $420 million in milestones and royalties on product sales. Precision will lead pre-clinical research while Lilly handles clinical development.
Precision BioSciences, a clinical-stage biotechnology company (DTIL), announced that Matt Kane and Derek Jantz will present at the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. The company's presentation is scheduled for January 13, 2021, from 2:00 - 2:40 p.m. ET. A live webcast of the event will be available on their website, with an archive accessible for 30 days post-presentation. Precision BioSciences is dedicated to advancing life through its ARCUS® genome editing platform, focusing on CAR T immunotherapy and gene correction therapies.
Precision BioSciences (Nasdaq: DTIL) announced the departure of Chief Financial Officer Abid Ansari after nearly five years, effective at the end of 2020, to pursue a new career opportunity. Alex Kelly, the Chief Corporate Affairs Officer, will serve as Interim CFO, while Shane Barton, Vice President and Corporate Controller, will be the interim principal accounting officer. CEO Matt Kane expressed gratitude for Ansari's contributions during a transformational phase for the company, emphasizing a focus on advancing their allogeneic CAR T cell therapy and in vivo gene correction pipelines.